It felt like something inside me wound up and sucker-punched me from the inside out. The air around me got heavy.
Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.